title: Targeted Therapies for Prostate Cancer.
abstract: New therapies for prostate cancer have emerged over the past three years. Nevertheless, none of these agents is curative, and unfortunately, patients often ultimately develop resistance to these agents. Therefore, the development of innovative and effective therapies that overcome these resistances is necessary. Unfortunately, the results of a phase III trial evaluating docetaxel in combination with targeted therapies demonstrated no difference in survival. Moreover, scarce data on the combination of a targeted therapy with new agents are currently available. New trials are investigating these possible combination treatments; the results of these (on-going) clinical studies are awaited.
authors.affiliation: Medical Oncology Unit, University of Siena , Siena , Italy 1.
authors.forename: Roberto
authors.initials: R
authors.lastname: Petrioli
authors.forename: Edoardo
authors.initials: E
authors.lastname: Francini
authors.forename: Anna Ida
authors.initials: AI
authors.lastname: Fiaschi
authors.forename: Letizia
authors.initials: L
authors.lastname: Laera
authors.forename: Giandomenico
authors.initials: G
authors.lastname: Roviello
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004353:Drug Evaluation, Preclinical; D019008:Drug Resistance, Neoplasm; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D008297:Male; D058990:Molecular Targeted Therapy / Q000379:methods*; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents
keywords: Biologic agents; Docetaxel; Prostate cancer; Target therapy